Age effect on bone mineral density changes in breast cancer patients receiving anastrozole: results from the ARBI prospective clinical trial
Journal of Cancer Research & Clinical Oncology, 05/08/2012
Markopoulos C et al. – The study suggests that younger postmenopausal women with normal bone mineral density (BMD) or mild osteopenia receiving A–only face an increased risk of bone loss in LS. Among patients with mild or severe osteopenia or osteoporosis treated with A + R, 12 months LS or HP BMD variations were configured regardless of age group.